News | October 18, 2010

First Canadian Hospital Implants Left Ventricular Assist System

October 18, 2010 – Toronto General Hospital is the first Canadian medical center to implant a left-ventricular assist system (LVAS) as part of a study for patients awaiting a heart transplant. The Peter Munk Cardiac Centre used the DuraHeart LVAS, by Terumo Heart, as part of the SUSTAIN BTT study.

The DuraHeart LVAS is designed to aid the pumping action of the heart in order to circulate blood throughout the body, and is for use in patients with end-stage heart failure. Due to the scarcity of donor organs, patients can be on the waiting list for months until a suitable donor becomes available.

“We are pleased to be the first center in Canada to bring this state-of-the-art technology to our heart failure patients,” said Vivek Rao, M.D., surgical director of the heart transplant program at The Peter Munk Cardiac Centre, and DuraHeart LVAS clinical investigator. “We look forward to being part of the landmark SUSTAIN trial evaluating the DuraHeart LVAS, which we believe is one of the most advanced left-ventricular assist devices currently available.”

The system incorporates a centrifugal flow rotary pump with a magnetically levitated impeller. The pump features three position sensors and electromagnetic coils that suspend the impeller inside the pump chamber without a single point of contact. The impeller’s active magnetic levitation is designed to eliminate friction by allowing a wide gap between blood contacting surfaces, enabling blood to flow through the pump unimpeded in a smooth, non-turbulent fashion.

The study was granted unconditional approval in early 2010 by the U.S. Food & Drug Administration (FDA). The DuraHeart LVAS already carries a CE Mark and is currently available for sale in European countries. The company has recently completed clinical trial enrollment for this device in Japan, and has submitted its Destination Therapy (DT) Investigational Device Exemption to the FDA, which is a first step in the process of obtaining approval to begin its DuraHeart DT Clinical Trial in the United States.

For more information: www.terumoheart.com

Related Content

Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Overlay Init